Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (6): 953-957. doi: 10.19723/j.issn.1671-167X.2023.06.001
琼 扶,霜 叶*(
)
CLC Number:
- R593.2
| 1 |
Wang L , Wang FS , Gershwin ME . Human autoimmune diseases: A comprehensive update[J]. J Intern Med, 2015, 278 (4): 369- 395.
doi: 10.1111/joim.12395 |
| 2 |
Arbuckle MR , McClain MT , Rubertone MV , et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus[J]. N Engl J Med, 2003, 349 (16): 1526- 1533.
doi: 10.1056/NEJMoa021933 |
| 3 |
Furie RA , Aroca G , Cascino MD , et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial[J]. Ann Rheum Dis, 2022, 81 (1): 100- 107.
doi: 10.1136/annrheumdis-2021-220920 |
| 4 |
Baker DJ , Arany Z , Baur JA , et al. CAR T therapy beyond cancer: The evolution of a living drug[J]. Nature, 2023, 619 (7971): 707- 715.
doi: 10.1038/s41586-023-06243-w |
| 5 |
Maldini CR , Ellis GI , Riley JL . CAR T cells for infection, autoimmunity and allotransplantation[J]. Nat Rev Immunol, 2018, 18 (10): 605- 616.
doi: 10.1038/s41577-018-0042-2 |
| 6 | Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases[J/OL]. Lancet, (2023-09-22)[2023-10-12]. https://doi.org/10.1016/S0140-6736(23)01126-1. |
| 7 |
Mougiakakos D , Krönke G , Völkl S , et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus[J]. N Engl J Med, 2021, 385 (6): 567- 569.
doi: 10.1056/NEJMc2107725 |
| 8 |
Mackensen A , Müller F , Mougiakakos D , et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus[J]. Nat Med, 2022, 28 (10): 2124- 2132.
doi: 10.1038/s41591-022-02017-5 |
| 9 |
Zhang W , Feng J , Cinquina A , et al. Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR[J]. Stem Cell Rev Rep, 2021, 17 (6): 2120- 2123.
doi: 10.1007/s12015-021-10251-6 |
| 10 |
Qin C , Tian DS , Zhou LQ , et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: Phase 1 trial interim results[J]. Signal Transduct Target Ther, 2023, 8 (1): 5.
doi: 10.1038/s41392-022-01278-3 |
| 11 |
Müller F , Boeltz S , Knitza J , et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome[J]. Lancet, 2023, 401 (10379): 815- 818.
doi: 10.1016/S0140-6736(23)00023-5 |
| 12 |
Pecher AC , Hensen L , Klein R , et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome[J]. JAMA, 2023, 329 (24): 2154- 2162.
doi: 10.1001/jama.2023.8753 |
| 13 |
Bergmann C , Müller F , Distler JHW , et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells[J]. Ann Rheum Dis, 2023, 82 (8): 1117- 1120.
doi: 10.1136/ard-2023-223952 |
| 14 |
Granit V , Benatar M , Kurtoglu M , et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): A prospective, multicentre, open-label, non-randomised phase 1b/2a study[J]. Lancet Neurol, 2023, 22 (7): 578- 590.
doi: 10.1016/S1474-4422(23)00194-1 |
| 15 |
Ellebrecht CT , Bhoj VG , Nace A , et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease[J]. Science, 2016, 353 (6295): 179- 184.
doi: 10.1126/science.aaf6756 |
| 16 |
Sun Y , Yuan Y , Zhang B , et al. CARs: A new approach for the treatment of autoimmune diseases[J]. Sci China Life Sci, 2023, 66 (4): 711- 728.
doi: 10.1007/s11427-022-2212-5 |
| 17 |
Riet T , Chmielewski M . Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges[J]. Front Immunol, 2022, 13, 934343.
doi: 10.3389/fimmu.2022.934343 |
| [1] | Jiayi TIAN, Yixue GUO, Xia ZHANG, Xiaolin SUN, Jing HE. Flow cytometry analysis of normal range of natural killer cells and their subsets in peripheral blood of healthy Chinese adults [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 839-844. |
| [2] | Yushu YANG, Xuan QI, Meng DING, Wei WANG, Huifang GUO, Lixia GAO. Diagnostic values of anti-salivary gland protein-1 antibody combined with anti-parotid secretory protein antibody for Sjögren's syndrome [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 845-852. |
| [3] | Hua ZHONG, Yuan LI, Liling XU, Mingxin BAI, Yin SU. Application of 18F-FDG PET/CT in rheumatic diseases [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 853-859. |
| [4] | Zhihui WU, Mingzhi HU, Qiaoying ZHAO, Fengfeng LV, Jingying ZHANG, Wei ZHANG, Yongfu WANG, Xiaolin SUN, Hui WANG. Immunomodulatory mechanism of umbilical cord mesenchymal stem cells modified by miR-125b-5p in systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 860-867. |
| [5] | Dongwu LIU, Jie CHEN, Mingli GAO, Jing YU. Rheumatoid arthritis with Castleman-like histopathology in lymph nodes: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 928-931. |
| [6] | Zhengfang LI,Cainan LUO,Lijun WU,Xue WU,Xinyan MENG,Xiaomei CHEN,Yamei SHI,Yan ZHONG. Application value of anti-carbamylated protein antibody in the diagnosis of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 729-734. |
| [7] | 佳佳 乔,聪 田,晓波 黄,军 刘. [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 745-749. |
| [8] | Huina HUANG,Jing ZHAO,Xiangge ZHAO,Ziran BAI,Xia LI,Guan WANG. Regulatory effect of lactate on peripheral blood CD4+ T cell subsets in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 519-525. |
| [9] | Limin REN,Chuchu ZHAO,Yi ZHAO,Huiqiong ZHOU,Liyun ZHANG,Youlian WANG,Lingxun SHEN,Wenqiang FAN,Yang LI,Xiaomei LI,Jibo WANG,Yongjing CHENG,Jiajing PENG,Xiaozhen ZHAO,Miao SHAO,Ru Li. Low disease activity and remission status of systemic lupus erythematosus in a real-world study [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 273-278. |
| [10] | Xiaofei TANG,Yonghong LI,Qiuling DING,Zhuo SUN,Yang ZHANG,Yumei WANG,Meiyi TIAN,Jian LIU. Incidence and risk factors of deep vein thrombosis in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 279-283. |
| [11] | Zhanhong LAI,Jiachen LI,Zelin YUN,Yonggang ZHANG,Hao ZHANG,Xiaoyan XING,Miao SHAO,Yuebo JIN,Naidi WANG,Yimin LI,Yuhui LI,Zhanguo LI. A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 284-292. |
| [12] | Yi-jun HAN,Chang-hong LI,Xiu-ying CHEN,Jin-xia ZHAO. Comparison of clinical and immunological characteristics between primary Sjögren's syndrome patients with positive and negative anti-SSB antibody [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1000-1006. |
| [13] | Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012. |
| [14] | Xue ZOU,Xiao-juan BAI,Li-qing ZHANG. Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1013-1021. |
| [15] | Wen-gen LI,Xiao-dong GU,Rui-qiang WENG,Su-dong LIU,Chao CHEN. Expression and clinical significance of plasma exosomal miR-34-5p and miR-142-3p in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1022-1027. |
|
||